Lessons Learned When Implementing A Risk Management Program
Source: United BioSource LLC (UBC)
By Annette Stemhagen, DrPH, FISPE Senior Vice President and Chief Science Officer, Safety, Epidemiology, Registries, and Risk Management
Insights into the type of REMS program which may be required can be found by looking at recently approved REMS or those already in the marketplace. The FDA often relies on precedents when determining REMS requirements. For some products, the FDA has required Shared System REMS; for these, multiple sponsors must operate together under one REMS. UBC has the knowledge gained from designing and implementing multiple REMS across different therapeutic areas and targeting different risks.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
This website uses cookies to ensure you get the best experience on our website. Learn more